Research programme: herpes simplex virus therapeutics - Assembly Biosciences
Latest Information Update: 31 Mar 2023
At a glance
- Originator Assembly Biosciences
- Class Antivirals; Small molecules
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Herpes simplex virus type 2 infections
Most Recent Events
- 31 Dec 2022 Assembly Biosciences has patents pending for compositions of matter and method of using for pan-herpes non-nucleoside polymerase inhibitors (NNPIs)
- 05 Sep 2022 Pharmacodynamics data from early research in Herpes simplex virus type 2 released by Assembly Biosciences (Assembly Biosciences website, August 2022)
- 29 Aug 2022 Research programme: herpes simplex virus therapeutics - Assembly Biosciences is available for licensing as of 29 Aug 2022. https://www.assemblybio.com/collaborations/